arrow
T

Tanja Fehm

heinrich heine university dusseldorf
H指数:83
被引数:3.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Motivations and experiences of high-risk men in risk-adapted prostate cancer early detection: A qualitative study

高风险男性在风险适应型前列腺癌早期检测中的动机与经历:一项定性研究

2026-05-230
OAAI
AGO Breast Commission recommendations for the surgical therapy of breast cancer: Working Group on Gynecologic Cancers (AGO) update 2025

AGO乳腺癌委员会关于乳腺癌手术治疗的建议:妇科肿瘤工作组(AGO)2025年更新

2025-09-170
PREAI
Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancer

在接受一线CDK4/6抑制剂治疗后,转移性激素受体阳性、HER2阴性乳腺癌患者选择化疗方案的预后影响

2025-08-050
OA
Real-world utilization of aromatase inhibitors, tamoxifen, and ovarian function suppression in premenopausal patients with early hormone receptor-positive, HER2-negative breast cancer with increased recurrence risk

绝经前早期激素受体阳性、HER2阴性且复发风险增加的乳腺癌患者中,芳香化酶抑制剂、他莫昔芬和卵巢功能抑制的实际情况应用。

BREAST
IF7.9
2025-06-010
OAAI
Clinical characteristics and prognostic factors in patients with breast cancer and leptomeningeal metastases from a large registry of BMBC

乳腺癌并发软脑膜转移患者的临床特征与预后因素:来自BMBC大型注册研究的数据

BREAST
IF7.9
2025-06-010
OAAI
Detection of minimal residual disease and prediction of recurrence in breast cancer using a plasma-only circulating tumor DNA assay

使用仅血浆循环肿瘤DNA检测方法对乳腺癌进行微小残留病灶检测和复发预测

2025-04-010
PRE
Cell-free tumor DNA analysis in advanced or metastatic breast cancer patients: mutation frequencies, testing intention, and clinical impact

晚期或转移性乳腺癌患者的无细胞肿瘤DNA分析: 突变频率,检测意图和临床影响

2024-12-240
OAAI
Molecular adaptation to neoadjuvant immunotherapy in triple-negative breast cancer
2024-11-010
OAAI
The impact of physical activity on progression-free and overall survival in metastatic breast cancer based on molecular subtype
2024-10-162
OAAI
Prognostic impact of selection criteria of current adjuvant endocrine therapy trials NATALEE and monarchE in postmenopausal HRpos/ HER2neg breast cancer patients treated with upfront letrozole
2024-09-012
OAAI